Safety
TEAE, SAD
ADVERSE EVENT
The safety analyses were performed on all 100 subjects who received flubentylosin or placebo: 36 subjects and 12 subjects, respectively, in Part 1, 12 subjects in Part 2, and 30 subjects and 10 subjects, respectively, in Part 3.In Part 1 (SAD), 16.7% of flubentylosin-treated subjects and 0% of placebo-treated subjects experienced at least one treatment-emergent adverse event (TEAE) (